Share on LinkedInShare on LinkedIn

ARTICLE · 02 MARCH 2018

What Does Actavis v Eli Lilly Mean For European Patent Litigation Strategy?

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

Doctrines of equivalents in France, Spain and Germany: How do local patent experts view the UK Supreme Court's judgment in Actavis v Eli Lilly?

European UnionIntellectual Property

Doctrines of equivalents in France, Spain and Germany: How do local patent experts view the UK Supreme Court's judgment in Actavis v Eli Lilly?

This article has been written jointly by the indicated authors and Carolina Pina of Garrigues. It is due to be published in The BioScience Law Review.

In a landmark judgment in July 2017, the UK Supreme Court introduced a doctrine of equivalents into modern UK patent law and by its application, refused Actavis' application for a declaration of non-infringement in respect of Eli Lilly's European patent number 1,313,508 ("EP '508") designating the UK.

The UK Supreme Court also denied Actavis' applications for declarations in respect of the French, Spanish and Italian designations of EP '508; the issue of infringement of the German designation, although originally in issue in the UK case, remains, at the time of writing, the subject of continuing litigation in Germany.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from